Roy A Whitfield - Net Worth and Insider Trading
Roy A Whitfield Net Worth
The estimated net worth of Roy A Whitfield is at least $51 Million dollars as of 2024-11-13. Roy A Whitfield is the Director of Incyte Corp and owns about 621,082 shares of Incyte Corp (INCY) stock worth over $50 Million. Roy A Whitfield is the Director of Illumina Inc and owns about 2,853 shares of Illumina Inc (ILMN) stock worth over $421,160. Roy A Whitfield is also the Director of Nektar Therapeutics and owns about 197,000 shares of Nektar Therapeutics (NKTR) stock worth over $260,040. Details can be seen in Roy A Whitfield's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Roy A Whitfield has not made any transactions after 2018-06-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Roy A Whitfield
Roy A Whitfield Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Roy A Whitfield owns 3 companies in total, including Nektar Therapeutics (NKTR) , Illumina Inc (ILMN) , and Incyte Corp (INCY) .
Click here to see the complete history of Roy A Whitfield’s form 4 insider trades.
Insider Ownership Summary of Roy A Whitfield
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NKTR | Nektar Therapeutics | 2018-06-06 | director |
| ILMN | Illumina Inc | 2016-08-12 | director |
| INCY | Incyte Corp | 2013-11-18 | director & other: Chairman |
Roy A Whitfield Latest Holdings Summary
Roy A Whitfield currently owns a total of 3 stocks. Among these stocks, Roy A Whitfield owns 621,082 shares of Incyte Corp (INCY) as of November 18, 2013, with a value of $50 Million and a weighting of 98.66%. Roy A Whitfield owns 2,853 shares of Illumina Inc (ILMN) as of August 12, 2016, with a value of $421,160 and a weighting of 0.83%. Roy A Whitfield also owns 197,000 shares of Nektar Therapeutics (NKTR) as of June 6, 2018, with a value of $260,040 and a weighting of 0.51%.
Latest Holdings of Roy A Whitfield
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| INCY | Incyte Corp | 2013-11-18 | 621,082 | 80.59 | 50,052,998 |
| ILMN | Illumina Inc | 2016-08-12 | 2,853 | 147.62 | 421,160 |
| NKTR | Nektar Therapeutics | 2018-06-06 | 197,000 | 1.32 | 260,040 |
Holding Weightings of Roy A Whitfield
Roy A Whitfield Form 4 Trading Tracker
According to the SEC Form 4 filings, Roy A Whitfield has made a total of 0 transactions in Incyte Corp (INCY) over the past 5 years. The most-recent trade in Incyte Corp is the sale of 50,000 shares on November 18, 2013, which brought Roy A Whitfield around $2 Million.
According to the SEC Form 4 filings, Roy A Whitfield has made a total of 0 transactions in Illumina Inc (ILMN) over the past 5 years. The most-recent trade in Illumina Inc is the sale of 4,000 shares on August 12, 2016, which brought Roy A Whitfield around $668,880.
According to the SEC Form 4 filings, Roy A Whitfield has made a total of 0 transactions in Nektar Therapeutics (NKTR) over the past 5 years. The most-recent trade in Nektar Therapeutics is the acquisition of 5,000 shares on June 6, 2018, which cost Roy A Whitfield around $290,200.
Insider Trading History of Roy A Whitfield
- 1
Roy A Whitfield Trading Performance
GuruFocus tracks the stock performance after each of Roy A Whitfield's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Roy A Whitfield is 45.55%. GuruFocus also compares Roy A Whitfield's trading performance to market benchmark return within the same time period. The performance of stocks bought by Roy A Whitfield within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Roy A Whitfield's insider trading performs compared to the benchmark.
Performance of Roy A Whitfield
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.75 | | | | | |
| Relative Return to S&P 500(%) | 1.5 | | | | | |
Roy A Whitfield Ownership Network
Ownership Network List of Roy A Whitfield
Ownership Network Relation of Roy A Whitfield
Roy A Whitfield Owned Company Details
What does Nektar Therapeutics do?
Who are the key executives at Nektar Therapeutics?
Roy A Whitfield is the director of Nektar Therapeutics. Other key executives at Nektar Therapeutics include SVP & General Counsel Mark Andrew Wilson , Chief R&D Officer Jonathan Zalevsky , and director & President & CEO Howard W Robin .
Nektar Therapeutics (NKTR) Insider Trades Summary
Over the past 18 months, Roy A Whitfield made no insider transaction in Nektar Therapeutics (NKTR). Other recent insider transactions involving Nektar Therapeutics (NKTR) include a net sale of 111,800 shares made by Howard W Robin , a net sale of 52,375 shares made by Jonathan Zalevsky , and a net sale of 41,460 shares made by Mark Andrew Wilson .
In summary, during the past 3 months, insiders sold 27,398 shares of Nektar Therapeutics (NKTR) in total and bought 0 shares, with a net sale of 27,398 shares. During the past 18 months, 289,853 shares of Nektar Therapeutics (NKTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 289,853 shares.
Nektar Therapeutics (NKTR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Nektar Therapeutics Insider Transactions
Roy A Whitfield Mailing Address
Above is the net worth, insider trading, and ownership report for Roy A Whitfield. You might contact Roy A Whitfield via mailing address: C/o Incyte Corporation, 3160 Porter Drive, Palo Alto Ca 93404.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
